Christophe Arbet-Engels

Christophe Arbet-Engels has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Altimmune, Inc. and X4 Pharmaceuticals, Inc. Over a trading history stretching from 23 January 2025 to 1 October 2026, the count stands at 4 filings.

The filings describe grants, exercises and other transfers rather than trades on the open market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.

The newest entry dates from 5 October 2026: an option exercise, in Altimmune, Inc. Typically, a trade is published a median of 4 days after it takes place. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.